Boston Scientific Kicks Off 2026 with Strategic Acquisition of Valencia Technologies to Expand Urology Portfolio

Jan 13, 2026 20:04 CST Updated 20:04

Valencia Technologies

Developer of Implantable Neurostimulation Devices

Axonics

Developer of Novel Implantable Neuromodulation Technologies

SoniVie

Medical Device Developer

Bolt Medical

Laser Intravascular Lithotripsy Catheter Developer

Author | Yue Qing

Source | CBI Devices

Boston Scientific Scores Another Win.

01
2026 Initial Purchase
Boston Scientific Further Increases Investment in the Urology Sector

January 12Day, waveBoston Scientific announced,CompletedAcquisitionValencia Technologies Final Agreement ReachedAgenda. This is waveBoston Scientific’s First Blockbuster Acquisition of 2026,The specific terms of the transaction have not been disclosed,

Valencia is a company located in Valencia, CaliforniaNeuromodulation Company, Dedicated to Improving Bladder FunctionStandard of Care for Disorders,itsDesigned and manufactured for the treatment of urgency urinary incontinence（UUI）eCoin® device, having just completed a $35 million financing round in early 2025.

Boston Scientific established an early presence in the urology field,Its initial product launches included catheters for bladder stone surgery, urology businessIn recent years, it has become a high-growth business segment.Revenue in Q3 2025$682 million, year-on-year increase28.1%，

ValenciaeCoinThe system is at2022received U.S.FDAApproved,Suitable for those who have completed percutaneous tibial nerve stimulation (PTNS) who have undergone testing with favorable outcomes, or for those requiring more conservativeUUIFor patients with treatment intolerance or suboptimal efficacy.

Meghan Scanlon, President of Boston Scientific’s Urology Division, stated: “Incorporating eCoin into Boston Scientific’s portfolio will drive our expansion into the implantable tibial nerve stimulation (ITNS) field, a high-growth new arena for our urology business. ITNS technology complements our existing pelvic health product line, and we look forward to providing more comprehensive treatment solutions for patients across the entire care continuum.”

InIn the urology sector, Boston Scientific has made significant moves in recent years. In 2024, it completed the $3.7 billion acquisition of Axonics, thereby ending the long-standing patent dispute between Axonics and Medtronic, and achieving technological and product leadership in the incontinence treatment arena.

According to the announcement,The acquisition is expected to be completed in the first half of 2026., at which time eCoin and the Axonics product series are expected to be integrated for sales, creating a new impact on the existing market landscape.

02
Intensive Multi-Sector Acquisitions
Boston Scientific ““Crazy Shopping Spree”

In 2025, Boston Scientific embarked on an aggressive acquisition spree, accelerating the expansion of its product and technology portfolio to engage in head-to-head competition with multi-sector giants.

Last March，Boston Scientific inIncreased Investment in the RDN Field, AnnouncingAcquired for approximately $360 millionSoniVieThe remaining 90% equity,It also includes regulatory milestone payments of up to $180 million,andMedtronic andReCor Medical Seizes This New Blue Ocean Market.

In April, Boston ScientificBolt MedicalThe Acquisition Is Finalized, Marking Official EntryIVLMarket, secured in 2024Shockwave's competition with Johnson & Johnson.

Time has come to October,WaveBoston Scientific has again reached an agreement to acquireNalu Medicalthe acquisition agreement, accelerating the layout in chronic pain management,ItsThe neuromodulation product portfolio will achieve comprehensive coverage of central and peripheral systems, as well as pain and functional disorders. The transaction is expected toTo be completed in the first half of 2026.

As can be seen from the above cases,As an established industry giant, Boston Scientific’s expansion strategy involved securing strategic investments in three companies across different sectors prior to formal acquisition. The product portfolios of these companies are highly synergistic with Boston Scientific’s existing lines, enabling the rapid formulation of new sales plans post-acquisition, minimizing integration time, and driving performance growth.

Meanwhile, high-growth performance is demonstrated asBoston Scientific’s major acquisition provides strong backing.

2025Q3Boston Scientific's net sales were50.65$100 million, compared to the same period last year,Report Growth20.3%, Operational Growth19.4%, organic growth15.3%。

By business line,MedSurgNet Sales17.22hundred million USD,Year-over-yearGrowth16.4%；CardiovascularBusinessNet Sales33.43hundred million USD, year-on-year growth22.4%。

Boston Scientific expects that,Compared to the same period last year,2025The net sales growth for the full year was approximately20%, organic growth was approximately15.5%。

From urology to cardiovascular care to chronic pain management,After years of aggressive investment, Boston Scientific’s product portfolio has become highly comprehensive, establishing a technological moat amid intense market competition. With the closure of multiple transactions, the giant’s market influence is poised to further strengthen.

END

Content inquiries: WeChat nrzx0321